Oulman Roxanne 4
4 · Klaviyo, Inc. · Filed Jul 24, 2026
Research Summary
AI-generated summary of this filing
Klaviyo (KVYO) Director Roxanne Oulman Converts 16,775 Shares
What Happened
Roxanne Oulman, a director of Klaviyo (KVYO), completed a conversion of 16,775 shares of the issuer's Series B Common Stock into 16,775 shares of Series A Common Stock on July 22, 2026. The filing records the acquisition of 16,775 Series A shares and the corresponding disposition of 16,775 Series B derivative shares at $0.00 — this was a conversion of share class, not a cash purchase or sale.
Key Details
- Transaction date: 2026-07-22; Form 4 filed: 2026-07-24 (timely within Section 16 reporting window).
- Transaction: Conversion of 16,775 Series B Common Stock into 16,775 Series A Common Stock. Disposition price reported as $0.00 (derivative conversion).
- Shares held after transaction (as reported): consists of 22,521 shares of Series A Common Stock and 14,822 unvested restricted stock units (each RSU represents the right to one share upon vesting) (see F3).
- Footnote F1: Series B shares convert 1:1 into Series A and have no expiration.
- Footnote F2: Some shares are held by the "Roxanne Oulman 2025 GRAT" for which the reporting person is trustee and disclaims beneficial ownership except to the extent of any pecuniary interest.
Context
A conversion of Series B into Series A is an administrative reclassification of share class and does not represent a market purchase or sale; no cash was received or paid. Such conversions typically do not indicate a change in insider sentiment on their own.
Insider Transaction Report
- Conversion
Series A Common Stock
[F1][F2]2026-07-22+16,775→ 16,775 total(indirect: By Roxanne Oulman 2025 GRAT) - Conversion
Series B Common Stock
[F1][F2]2026-07-22−16,775→ 29,891 total(indirect: By Roxanne Oulman 2025 GRAT)→ Series A Common Stock (16,775 underlying)
- 37,343
Series A Common Stock
[F3] - 15,165
Series B Common Stock
[F1]→ Series A Common Stock (15,165 underlying)
Footnotes (3)
- [F1]Each share of the Issuer's Series B Common Stock, par value $0.001 per share ("Series B Common Stock"), is convertible at any time at the option of the holder into one share of the Issuer's Series A Common Stock, par value $0.001 per share ("Series A Common Stock"), and will automatically convert into one share of Series A Common Stock upon the occurrence of certain events as set forth in the Issuer's certificate of incorporation. The Series B Common Stock has no expiration date.
- [F2]Shares held by Roxanne Oulman 2025 GRAT, of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose.
- [F3]Consists of (i) 22,521 shares of Series A Common Stock and (ii) 14,822 unvested restricted stock units awarded under the Issuer's 2023 Stock Option and Incentive Plan, each representing the contingent right to receive one share of Series A Common Stock upon vesting and settlement.